Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Dr Skrypets on an Analysis of Clinical Features of Older Patients With PTCL

June 12th 2025

Tetiana Skrypets, MD, PhD, discusses next steps for researching the clinical features and treatment outcomes of older patients with PTCL.

T-DXd Plus Pertuzumab Could Redefine First-Line HER2+ Breast Cancer Management: With Paolo Tarantino, MD

June 11th 2025

Paolo Tarantino, MD, discusses key updates in HER2-positive breast cancer presented at the 2025 ASCO Annual Meeting

Darolutamide/ADT Combo Delays Pain Progression and Enhances QOL in mHSPC

June 11th 2025

Alicia Morgans, MD, MPH, discusses findings from a QOL analysis of the ARANOTE trial, which evaluated darolutamide plus ADT in patients with mHSPC.

EV-302 Regimen Shows Sustained Efficacy Vs Chemo Across Key Subgroups of Urothelial Cancer

June 10th 2025

First-line enfortumab vedotin plus pembrolizumab continued to demonstrate efficacy across subgroups of locally advanced or metastatic urothelial carcinoma.

Telisotuzumab Vedotin Shakes Up Management of Pretreated, c-MET–Overexpressing NSCLC: With Jonathan W. Goldman, MD

June 10th 2025

Jonathan W. Goldman, MD, discusses the role of telisotuzumab vedotin in c-MET protein–overexpressing, nonsquamous, EGFR wild-type NSCLC.

China’s Center for Drug Evaluation Accepts MAA for Pimicotinib in TGCT

June 10th 2025

The Center for Drug Evaluation of the Chinese NMPA has accepted the marketing authorization application for pimicotinib in patients with TGCT.

First-Line Lurbinectedin Plus Atezolizumab Maintenance Under Priority Review for ES-SCLC

June 10th 2025

The FDA granted priority review to the sNDA seeking the approval of the first-line maintenance combination of lurbinectedin and atezolizumab for ES-SCLC.

Olaparib Plus Radium-223 Doubles rPFS vs Radium-223 Alone in mCRPC

June 10th 2025

Rana R. McKay, MD, discusses data from the COMRADE trial, which showed that olaparib plus radium-223 improved rPFS in men with mCRPC with bone metastases.

Collaborative Structural Reforms Represent a Way Forward for Oncology Innovations: With Elizabeth Mittendorf, MD, PhD, MHCM

June 9th 2025

Dr Mittendorf shares how ASCO plans to address the implications of federal research funding cuts and how structural reforms may bolster oncology progress.

Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target

June 9th 2025

Daneng Li, MD, discusses the IL-27–targeted agent casdozokitug in hepatocellular carcinoma.

Dr Mittendorf on Expanding ASCO’s Mission Through Research Advocacy and Global Collaboration

June 6th 2025

Elizabeth Mittendorf, MD, PhD, MHCM, discusses advancing ASCO’s mission through research advocacy, global collaboration, and a commitment to equity.

Dr Rugo on Research Needed to Clarify the Role of T-DXd Plus Pertuzumab in HER2+ Breast Cancer

June 6th 2025

Hope Rugo, MD, discusses the application of findings from the DESTINY-Breast09 trial of T-DXd plus pertuzumab in HER2-positive breast cancer.

Dr Rugo on Ongoing ADC Investigations Set to Shift Practice in HER2+ Breast Cancer

June 6th 2025

Hope Rugo, MD, discusses the evolving use of antibody-drug conjugates in HER2-positive breast cancer.

Experts Underscore the Top Abstracts to Watch at the 2025 EHA Congress

June 6th 2025

Experts highlight key abstracts to watch for at the 2025 EHA Congress.

Dr Haas on 5-Year Outcomes With Adjuvant Pembrolizumab in ccRCC

June 5th 2025

Naomi B. Haas, MD, shares 5-year follow-up data with adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.

Bispecific Antibodies Improve TTNT and Reshape R/R Follicular Lymphoma Management

June 5th 2025

Vivek Patel, MD, discusses the growing body of data supporting the use of bispecific antibodies in patients with relapsed/refractory follicular lymphoma.

Epcoritamab Maintains Responses at 3 Years in Relapsed/Refractory LBCL

June 5th 2025

Epcoritamab monotherapy yielded durable remissions and survival benefits in relapsed/refractory LBCL that remained in CR 2 years after starting treatment.

Dr Mittendorf Charts Vision as ASCO President-Elect to Advance Multidisciplinary Care and Research Equity

June 5th 2025

Elizabeth Mittendorf, MD, PhD, shares her ASCO priorities: expanding trial access, strengthening teams, and advancing global, evidence-based oncology care.

THIO Plus Cemiplimab Shows Activity and Is Safe in ICI-Resistant Advanced NSCLC

June 4th 2025

THIO plus cemiplimab showed tolerability and activity in ICI-resistant advanced NSCLC in the second- and third-line settings.

BNT327/PM8002 Plus Chemo Is Active in Unresectable Pleural and Peritoneal Mesothelioma

June 4th 2025

Frontline BNT327/PM8002 plus chemotherapy was effective and safe in patients with unresectable pleural and peritoneal mesothelioma.